RU2211704C2 - Модифицированный фактор vii - Google Patents

Модифицированный фактор vii Download PDF

Info

Publication number
RU2211704C2
RU2211704C2 RU99100089/14A RU99100089A RU2211704C2 RU 2211704 C2 RU2211704 C2 RU 2211704C2 RU 99100089/14 A RU99100089/14 A RU 99100089/14A RU 99100089 A RU99100089 A RU 99100089A RU 2211704 C2 RU2211704 C2 RU 2211704C2
Authority
RU
Russia
Prior art keywords
phe
arg
factor vii
chloromethylketone
proteinase inhibitor
Prior art date
Application number
RU99100089/14A
Other languages
English (en)
Russian (ru)
Other versions
RU99100089A (ru
Inventor
Ларс Кристиан ПЕТЕРСЕН (DK)
Ларс Кристиан Петерсен
Чарльз Э. ХАРТ (US)
Чарльз Э. Харт
Улла ХЕДНЕР (SE)
Улла Хеднер
Мирелла Эсбан РАСМУССЕН (DK)
Мирелла Эсбан Расмуссен
Original Assignee
Ново Нордиск А/С
Займоджинетикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С, Займоджинетикс Инк. filed Critical Ново Нордиск А/С
Publication of RU99100089A publication Critical patent/RU99100089A/ru
Application granted granted Critical
Publication of RU2211704C2 publication Critical patent/RU2211704C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU99100089/14A 1996-06-07 1997-06-06 Модифицированный фактор vii RU2211704C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/660,289 US5833982A (en) 1991-02-28 1996-06-07 Modified factor VII
US08/660,289 1996-06-07

Publications (2)

Publication Number Publication Date
RU99100089A RU99100089A (ru) 2000-11-27
RU2211704C2 true RU2211704C2 (ru) 2003-09-10

Family

ID=24648892

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99100089/14A RU2211704C2 (ru) 1996-06-07 1997-06-06 Модифицированный фактор vii

Country Status (17)

Country Link
US (2) US5833982A (Direct)
EP (1) EP0910580A1 (Direct)
JP (1) JP2000513720A (Direct)
KR (1) KR20000016415A (Direct)
CN (2) CN1515318A (Direct)
AU (1) AU735012B2 (Direct)
BR (1) BR9709661A (Direct)
CA (1) CA2256761A1 (Direct)
CZ (1) CZ394698A3 (Direct)
HU (1) HUP0003077A3 (Direct)
IL (1) IL127099A0 (Direct)
NO (1) NO985668L (Direct)
PL (1) PL330365A1 (Direct)
RU (1) RU2211704C2 (Direct)
UA (1) UA68333C2 (Direct)
WO (1) WO1997047651A1 (Direct)
ZA (1) ZA975013B (Direct)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
JP2001510168A (ja) * 1997-07-18 2001-07-31 ノボ ノルディスク アクティーゼルスカブ ＦＶＩＩａ媒介性細胞内シグナル伝達経路に関連する反対条件の処理のためのＦＶＩＩａ又はＦＶＩＩａｉの使用
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6406488B1 (en) 1998-08-27 2002-06-18 Heartstent Corporation Healing transmyocardial implant
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
EP1982732A3 (en) 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
WO2001097752A2 (en) * 2000-06-20 2001-12-27 The Trustees Of The University Of Pennsylvania Compositions comprising urokinase for modulating muscle contractility and angiogenisis
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
JP4274522B2 (ja) 2000-12-06 2009-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｘａ因子阻害剤としてのグアニジンおよびアミジン誘導体
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
EP1373493B1 (en) * 2001-03-22 2013-07-31 Novo Nordisk Health Care AG Coagulation factor vii derivative
WO2002087605A2 (en) * 2001-05-02 2002-11-07 Novo Nordisk A/S Modified fvii in treatment of ards
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
WO2003022122A2 (en) * 2001-09-10 2003-03-20 Florence Medical Ltd. Individual ffr determination for lesions of a multi-lesioned blood vessel
ES2466024T3 (es) 2001-10-10 2014-06-09 Ratiopharm Gmbh Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF)
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2002336920A1 (en) * 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
PL370652A1 (en) * 2001-12-21 2005-05-30 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
EP1458407A1 (en) * 2001-12-21 2004-09-22 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
NZ536340A (en) * 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP1503798B8 (en) * 2002-05-03 2012-03-14 Novo Nordisk Health Care AG Stabilised solid compositions of modified factor vii
DK2283856T3 (da) 2002-06-21 2017-11-20 Novo Nordisk Healthcare Ag Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
ATE505487T1 (de) * 2002-09-30 2011-04-15 Bayer Healthcare Llc Fvii- oder fviia-varianten mit erhöhter koagulationswirkung
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
ES2327044T3 (es) * 2003-03-20 2009-10-23 Bayer Healthcare Llc Variantes de fvii o fviia.
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
JP5627832B2 (ja) * 2003-05-23 2014-11-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 溶液中におけるタンパク質の安定化
US7029675B1 (en) * 2003-06-04 2006-04-18 Shu-Wha Lin Hepsin antagonist and methods of use
WO2004111242A1 (en) * 2003-06-19 2004-12-23 Maxygen Holdings Ltd. FACTOR VII OR VIIa GLA DOMAIN VARIANTS
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
AU2004298789A1 (en) * 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
EP1797180A2 (en) * 2004-09-29 2007-06-20 Novo Nordisk Health Care AG Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
EP2626079A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjungated factor VIII molecules
EP2379096B1 (en) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
KR101294351B1 (ko) * 2010-05-27 2013-08-07 동국대학교 산학협력단 뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
PT3564260T (pt) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
NZ724133A (en) 2012-03-21 2020-07-31 Baxalta Inc Tfpi inhibitors and methods of use
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
KR20180034518A (ko) * 2015-07-22 2018-04-04 아이코닉 테라퓨틱스, 인코포레이티드 혈관신생 및 신혈관형성 관련 장애를 치료하는 방법
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
AU2017206445B2 (en) 2016-01-15 2019-07-18 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18F-labled active site inhibited factor VII
WO2018091058A1 (en) 2016-11-17 2018-05-24 Rigshospitalet 177-lu labeled active site inhibited factor vii
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2022561C1 (ru) * 1991-03-05 1994-11-15 Харьковский государственный университет им.А.М.Горького Противоишемическое средство
WO1994027631A1 (en) * 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
WO1996006637A1 (en) * 1994-08-26 1996-03-07 Washington University Method of inhibiting tissue ischemia and reperfusion injury

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
EP0218713B1 (en) * 1985-04-22 1992-03-25 Genetics Institute, Inc. High yield production of active factor ix
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4829052A (en) * 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
JPS63290852A (ja) 1987-02-10 1988-11-28 グラクソ、グループ、リミテッド 化合物
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
EP0391999A4 (en) * 1988-09-23 1991-03-13 Corvas, Inc. Peptidyl inhibitors of the initiation of coagulation
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
DE69131292T2 (de) 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
ATE273393T1 (de) * 1991-02-28 2004-08-15 Zymogenetics Inc Modifizierter faktor-vii
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
GB9301093D0 (en) * 1993-01-20 1993-03-10 Rca Thomson Licensing Corp Digital video tape recorder for digital hdtv

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2022561C1 (ru) * 1991-03-05 1994-11-15 Харьковский государственный университет им.А.М.Горького Противоишемическое средство
WO1994027631A1 (en) * 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
WO1996006637A1 (en) * 1994-08-26 1996-03-07 Washington University Method of inhibiting tissue ischemia and reperfusion injury

Also Published As

Publication number Publication date
PL330365A1 (en) 1999-05-10
BR9709661A (pt) 2000-04-25
US5833982A (en) 1998-11-10
JP2000513720A (ja) 2000-10-17
NO985668D0 (no) 1998-12-04
CN1515318A (zh) 2004-07-28
UA68333C2 (en) 2004-08-16
EP0910580A1 (en) 1999-04-28
CN1131872C (zh) 2003-12-24
CA2256761A1 (en) 1997-12-18
AU3090697A (en) 1998-01-07
HUP0003077A2 (hu) 2000-12-28
NO985668L (no) 1999-02-04
CZ394698A3 (cs) 1999-04-14
WO1997047651A1 (en) 1997-12-18
ZA975013B (en) 1997-12-08
KR20000016415A (ko) 2000-03-25
US6168789B1 (en) 2001-01-02
CN1221427A (zh) 1999-06-30
IL127099A0 (en) 1999-09-22
AU735012B2 (en) 2001-06-28
HUP0003077A3 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
RU2211704C2 (ru) Модифицированный фактор vii
RU99100089A (ru) Модифицированный фактор vii
Heriot et al. A review of techniques for liver resection
Erdos Angiotensin I Converting Enzyme and the Changes in Our Concepts Through the Years Memorial Lecture: Lewis K. Dahl
Erdös Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture.
Wilhelm et al. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice
Chauhan et al. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease
ECSP034493A (es) Inhibidores de proteasa peptidomimeticos
Laschinger et al. Adjunctive left ventricular unloading during myocardial reperfusion plays a major role in minimizing myocardial infarct size
WO1996035788A3 (en) Kunitz type protease inhibitors
Mitsuoka et al. Protease inhibition in the intestinal lumen: attenuation of systemic inflammation and early indicators of multiple organ failure in shock
DK1107737T3 (da) Mikropartikler til anvendelse ved nålelös injektion
RU2000111513A (ru) Стирилсульфоновые средства против рака
Lefer et al. Cardioprotective effects of enalapril in acute myocardial ischemia
Riewald et al. Treatment options for clinically recognized disseminated intravascular coagulation
RU96119472A (ru) Ирригационный раствор для офтальмологии
Sum et al. Pathogenesis of bile-induced acute pancreatitis in the dog: experiments with detergents
Key et al. Coagulation inhibition for sepsis
Stier Jr et al. Beneficial action of beraprost sodium, a prostacyclin analog, in stroke-prone rats
Li et al. Evaluation of partial hepatectomy for primary liver carcinoma
Lung et al. Hibernoma: report of two cases
Fine et al. Mechanism of action of bacterial endotoxin
Mori et al. Inhibition of growth of HeLa cells by new synthetic protease inhibitors
Fernandez et al. Cardiomyopathy produced in rats with acute renal hypertension
JP2004538239A5 (Direct)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050607